Moberg Pharmas Year-end report 2020
Financing for both MOB-015 and BUPIPERIOD (JUL 2019-DEC 2020) · Net revenue SEK 50.5 million (15.6) * · EBITDA SEK 19.8 million (-1.7) * · Operating profit (EBIT) SEK 16.0 million (-3.0) * · Profit after tax SEK 10.2 million (-3.8) * · Total profit SEK 8.6 million (499.4) · Diluted earnings per share SEK 0.54 (-0.21) * · Cash and cash equivalents amounted to SEK 29.3 million (919.1) Comparative figures for the period refer to January 2019 - June 2019 (Note: 18 months vs. 6 months due to shortened fiscal year) SIXTH QUARTER (OCT-DEC 2020) · Net revenue SEK 0.